{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Engelen MM"],"funding":["Fonds Wetenschappelijk Onderzoek"],"pagination":["e12826"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9618401"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(7)"],"pubmed_abstract":["Background
Thromboinflammation plays a central role in severe COVID-19. The kallikrein pathway activates both inflammatory pathways and contact-mediated coagulation. We investigated if modulation of the thromboinflammatory response improves outcomes in hospitalized COVID-19 patients.Methods
In this multicenter open-label randomized clinical trial (EudraCT 2020-001739-28), patients hospitalized with COVID-19 were 1:2 randomized to receive standard of care (SOC) or SOC plus study intervention. The intervention consisted of aprotinin (2,000,000 IE IV four times daily) combined with low molecular weight heparin (LMWH; SC 50 IU/kg twice daily on the ward, 75 IU/kg twice daily in intensive care). Additionally, patients with predefined hyperinflammation received the interleukin-1 "],"journal":["Research and practice in thrombosis and haemostasis"],"pubmed_title":["Modulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn-Antico study."],"pmcid":["PMC9618401"],"funding_grant_id":["G0G4720N"],"pubmed_authors":["Heytens L","De Tavernier B","Ceunen H","Van Thillo Q","Wouters C","Robberecht W","Dupont L","Ruttens D","Liesenborghs L","Dolhain J","Engelen MM","Van Wijngaerden E","Vos R","Servaes V","Wauters J","Meyfroidt G","Hoppenbrouwers M","Wens K","Vandenbriele C","Cludts K","Gunst J","Neyts J","Spalart V","Mesotten D","Spriet I","Van den Berghe G","Devos T","Jacobs C","Dauwe D","Janssens W","Meersseman P","Roebroek D","Claes K","Belmans A","Van Geet C","Smet N","Devooght C","Daems K","Rex S","Verhamme P","De Munter P","Thomeer M","Betrains A","Verbeke G","Fivez T","Dreesen P","Vanassche T","Ockerman A","Martens CP","Debaveye B","D'hondt M","Wilmer A","DAWn Consortium Members","Dapper I","Vanheule K","Tuyls S","Gyselinck I"],"additional_accession":[]},"is_claimable":false,"name":"Modulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn-Antico study.","description":"Background
Thromboinflammation plays a central role in severe COVID-19. The kallikrein pathway activates both inflammatory pathways and contact-mediated coagulation. We investigated if modulation of the thromboinflammatory response improves outcomes in hospitalized COVID-19 patients.Methods
In this multicenter open-label randomized clinical trial (EudraCT 2020-001739-28), patients hospitalized with COVID-19 were 1:2 randomized to receive standard of care (SOC) or SOC plus study intervention. The intervention consisted of aprotinin (2,000,000 IE IV four times daily) combined with low molecular weight heparin (LMWH; SC 50 IU/kg twice daily on the ward, 75 IU/kg twice daily in intensive care). Additionally, patients with predefined hyperinflammation received the interleukin-1 ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-27T20:42:27.033Z","creation":"2026-04-08T01:48:54.355Z"},"accession":"S-EPMC9618401","cross_references":{"pubmed":["36324831"],"doi":["10.1002/rth2.12826"]}}